according to the Globally Harmonized System



# **Temozolomide Injection Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 27568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014

### **1. PRODUCT AND COMPANY IDENTIFICATION**

Product name	:	Temozolomide Injection Formulation
Manufacturer or supplier's de	eta	ils
Company	:	MSD
Address	:	Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207
Telephone	:	+1-908-740-4000
Emergency telephone number	:	+1-908-423-6000
E-mail address	:	EHSDATASTEWARD@msd.com
Recommended use of the ch	em	ical and restrictions on use
Recommended use Restrictions on use	:	Pharmaceutical Not applicable

### 2. HAZARDS IDENTIFICATION

### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification Acute toxicity (Oral)	:	Category 3
Serious eye damage/eye irri- tation	:	Category 2A
Germ cell mutagenicity	:	Category 2
Carcinogenicity	:	Category 2
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Bone marrow, thymus gland, Lymph nodes, spleen)
GHS label elements		

#### **GHS** label elements

Hazard pictograms :

according to the Globally Harmonized System



## **Temozolomide Injection Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 27568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014		
Signa	al word	: Danger			
Haza	Hazard statements		H301 Toxic if swallowed. H319 Causes serious eye irritation. H341 Suspected of causing genetic defects. H351 Suspected of causing cancer. H360FD May damage fertility. May damage the unborn child H373 May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.		
Preca	autionary statements	P260 Do n P264 Wasl P270 Do n	in, read and follow all safety instructions before use. ot breathe dust. n hands thoroughly after handling. ot eat, drink or smoke when using this product. r protective gloves/ protective clothing/ eye protec-		
		cal help im P305 + P3 for several easy to do P318 IF ex	: 16 + P330 IF SWALLOWED: Get emergency medi- mediately. Rinse mouth. 51 + P338 IF IN EYES: Rinse cautiously with water minutes. Remove contact lenses, if present and . Continue rinsing. posed or concerned, get medical advice. 17 If eye irritation persists: Get medical help.		
		<b>Storage:</b> P405 Store	e locked up.		
		<b>Disposal:</b> P501 Dispo disposal pl	ose of contents/ container to an approved waste ant.		

#### Other hazards which do not result in classification

:

Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture	


#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Citric acid	77-92-9	>= 10 - < 20
Sodium chloride	7647-14-5	>= 10 - < 20
Temozolomide	85622-93-1	>= 5 - < 10

### 4. FIRST AID MEASURES

General advice

In the case of accident or if you feel unwell, seek medical advice immediately.





Version Revision 9.0 28.09.20		-	S Number: 668-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014		
			When symptoms	persist or in all cases of doubt seek medical		
If inhaled		: If inhaled, remove to fresh air.				
In case of skin co	In case of skin contact		<ul> <li>Get medical attention.</li> <li>In case of contact, immediately flush skin with soap and plenty of water.</li> <li>Remove contaminated clothing and shoes.</li> <li>Get medical attention.</li> </ul>			
In case of eye co	ontact		Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.			
If swallowed		:	If swallowed, DO Call a physician o Rinse mouth thore	NOT induce vomiting. r poison control centre immediately.		
Most important s and effects, both delayed		:	Toxic if swallowed Causes serious e Suspected of cau Suspected of cau May damage ferti May cause damage exposure if swallo	d. ye irritation. sing genetic defects. sing cancer. lity. May damage the unborn child. ge to organs through prolonged or repeated		
Protection of first Notes to physicia			First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). Treat symptomatically and supportively.			
5. FIREFIGHTING MI						
Suitable extingui	shing media	•	Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical			
Unsuitable exting media	guishing	:	None known.			
Specific hazards fighting	during fire-	:	concentrations, ai potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. bustion products may be a hazard to health.		
Hazardous comb ucts	oustion prod-	:	Carbon oxides Nitrogen oxides (I Metal oxides Chlorine compour			
Specific extinguis ods	shing meth-	:	cumstances and t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers.		






# **Temozolomide Injection Formulation**

Versior 9.0		Revision Date: 28.09.2024		S Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
				Remove undamag so. Evacuate area.	ged containers from fire area if it is safe to do
	ecial   r firefig		:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.
6. ACC	IDEN	TAL RELEASE MEAS	SUF	RES	
tiv	e equi	l precautions, protec- pment and emer- rocedures	:		ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).
En	nvironr	nental precautions	:	Retain and dispos	akage or spillage if safe to do so. e of contaminated wash water. should be advised if significant spillages
	Methods and materials for containment and cleaning up		:	tainer for disposal Avoid dispersal of with compressed a Dust deposits sho es, as these may leased into the atr Local or national r posal of this mate employed in the c mine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

### 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use.





# **Temozolomide Injection Formulation**


Version 9.0	Revision Date: 28.09.2024	SDS Number: 27568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
	itions for safe storage ials to avoid	<ul> <li>Take precautional</li> <li>Do not eat, drink</li> <li>Take care to prevention</li> <li>environment.</li> <li>Keep in properly</li> <li>Store locked up.</li> <li>Keep tightly close</li> <li>Store in accordant</li> <li>Do not store with</li> </ul>	
		Explosives	

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
Temozolomide	85622-93-1	exposure) TWA	concentration 0.1 ug/m3 (OEB	Internal
			5)	
		Wipe limit	1 µg/100 cm2	Internal

Engineering measures	Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre- vent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment tech- nology designed to prevent leakage of compounds into the workplace.
Personal protective equipmer	t
Respiratory protection : Filter type : Hand protection	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Particulates type
Material :	Chemical-resistant gloves
Remarks : Eye protection : Skin and body protection :	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat.
	work driftenn of laboratory coat.





# **Temozolomide Injection Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 26.09.2023
9.0		27568-00025	Date of first issue: 03.11.2014
Hygie	ne measures	being perform suits) to avoid Use appropria contaminated : If exposure to flushing system place. When using do Wash contami The effective of engineering co appropriate de industrial hygio	y garments should be used based upon the task ed (e.g., sleevelets, apron, gauntlets, disposable exposed skin surfaces. te degowning techniques to remove potentially clothing. chemical is likely during typical use, provide eye ms and safety showers close to the working o not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, ene monitoring, medical surveillance and the strative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available

according to the Globally Harmonized System



# **Temozolomide Injection Formulation**

Version 9.0	Revision Date: 28.09.2024	SDS Number: 27568-00025		Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
W Parti octar	bility(ies) /ater solubility tion coefficient: n- nol/water	: No	uble t applicable	
Auto-ignition temperature Decomposition temperature			data available data available	
	iscosity, kinematic		t applicable	
·	osive properties		t explosive e substance o	r mixture is not classified as oxidizing.
Mole	cular weight		data available	
	cle characteristics cle size	: No	data available	9

### **10. STABILITY AND REACTIVITY**

Reactivity Chemical stability Possibility of hazardous reac- tions	: :	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials Hazardous decomposition	:	Oxidizing agents No hazardous decomposition products are known.
products	•	

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity		
Toxic if swallowed.		
Product:		
Acute oral toxicity	:	Acute toxicity estimate: 241.75 mg/kg Method: Calculation method
Components:		
Citric acid:		

according to the Globally Harmonized System



	-			
/ersion 9.0	Revision Date: 28.09.2024		0S Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
Acute	e oral toxicity	:	LD50 (Mouse):	5,400 mg/kg
Acute	e dermal toxicity	:		000 mg/kg Test Guideline 402 le substance or mixture has no acute dermal
II Sodii	um chloride:			
	e oral toxicity	:	LD50 (Rat): 3,5	50 ma/ka
	inhalation toxicity	:	LC50 (Rat): > 4 Exposure time: Test atmospher	1 h
Acute	e dermal toxicity	:	LD50 (Rabbit): :	> 5,000 mg/kg
II Toma	ozolomide:			
	e oral toxicity	:	LD50 (Dog): 19	mg/kg
	,		LD50 (Rat): 315	
			LD50 (Mouse):	
Com Citric		iiabie :	Rabbit	
Metho Resu		:	OECD Test Gui No skin irritatior	
Sodiu	um chloride:			
Speci Resu		:	Rabbit No skin irritatior	
	ous eye damage/eye in		on	
	es serious eye irritatior	1.		
	ponents:			
Speci	es		Rabbit	
Metho	bc	:	OECD Test Gui	
Resu	lt	:	Irritation to eyes	, reversing within 21 days
	um chloride:			
Speci Resu		:	Rabbit No eye irritation	
Inesu			ino eye imalion	

according to the Globally Harmonized System



Temoz	olomide Inject	ion F	ormulatio	n
Version 9.0	Revision Date: 28.09.2024		9S Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
Posr	piratory or skin sens	iticatio	n	
-	sensitisation	nisanc	11	
-	classified based on av	ailable	information.	
-	biratory sensitisatior			
Not c	classified based on av	ailable	information.	
<u>Com</u>	ponents:			
	um chloride:			
Test	Type sure routes	:	Local lymph n Skin contact	ode assay (LLNA)
Spec		•	Mouse	
Resu		:	negative	
Temo	ozolomide:			
Test		:	Maximisation <sup>-</sup>	Test
	sure routes	:	Dermal	
Spec Resu		:	Guinea pig negative	
Gern	n cell mutagenicity			
	ected of causing gene	etic def	ects.	
<u>Com</u>	ponents:			
Citric	c acid:			
Geno	otoxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
			Test Type: in Result: positiv	<i>v</i> itro micronucleus test e
			Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
Geno	otoxicity in vivo	:		

### Sodium chloride:

Н

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: positive
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative

Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro) Result: positive

according to the Globally Harmonized System



Version 9.0	Revision Date: 28.09.2024		DS Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
			thesis in mammal	lamage and repair, unscheduled DNA syn- ian cells (in vitro)
			Result: positive Test Type: Chrom Result: positive	nosome aberration test in vitro
			Test Type: Chrom Result: negative	nosome aberration test in vitro
Gend	otoxicity in vivo	:	Species: Mouse	e micronucleus test : Intraperitoneal injection
			cytogenetic test, o Species: Rat	enicity (in vivo mammalian bone-marrow chromosomal analysis) e: Intraperitoneal injection
	n cell mutagenicity - essment	:	Weight of evidend cell mutagen.	ce does not support classification as a germ
Tem	ozolomide:			
Gene	otoxicity in vitro	:	Test Type: Bacter Result: positive	rial reverse mutation assay (AMES)
			Test Type: Chrom Test system: Hun Result: positive	nosome aberration test in vitro nan lymphocytes
	n cell mutagenicity - essment	:		om in vitro mammalian mutagenicity assays, e activity relationship to known germ cell
II Carc	inogenicity			
	pected of causing cancer.			
Com	ponents:			
	ium chloride:			
	ication Route osure time	:	Rat Ingestion 2 Years negative	
Tem	ozolomide:			
Spec Appl		:	Rat Oral 6 Months	

\_

according to the Globally Harmonized System



## **Temozolomide Injection Formulation**

Version 9.0	Revision Date: 28.09.2024		S Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
Result Target	Organs	:	4 mg/kg body weig positive Mammary gland	ght
Carcino ment	ogenicity - Assess-	:	Limited evidence	of carcinogenicity in animal studies
•	<b>luctive toxicity</b> mage fertility. May dan	nage	e the unborn child.	
Compo	onents:			
Citric a Effects ment	acid: on foetal develop-	:	Test Type: One-ge Species: Rat Application Route Result: negative	eneration reproduction toxicity study
	olomide:			
Effects	on fertility	:	Species: Rat, mal Application Route	
Effects ment	on foetal develop-	:	Species: Rat Application Route Embryo-foetal tox	o-foetal development : Oral city: LOAEL: 13 mg/kg body weight lalformations were observed.
Reprod sessme	luctive toxicity - As- ent	:	ity, based on anim	adverse effects on sexual function and fertil- al experiments., Clear evidence of adverse ment, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### Components:

#### Citric acid:

Assessment

: May cause respiratory irritation.

### STOT - repeated exposure

May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

### Components:

### Temozolomide:

Exposure routes	: Ingestion
Target Organs	: Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	: Causes damage to organs through prolonged or repeated
11	exposure.

according to the Globally Harmonized System



/ersion ).0	Revision Date: 28.09.2024	SDS Number: 27568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
-	ated dose toxicity		
<u>Comp</u>	oonents:		
Citric	acid:		
Speci		: Rat	
NOAE LOAE		: 4,000 mg/kg : 8,000 mg/kg	
	ation Route	: Ingestion	
	sure time	: 10 Days	
Sodiu	ım chloride:		
Speci		: Rat	
LOAE	L ation Route	: 2,533 mg/kg : Ingestion	
	sure time	: 2 yr	
Temo	zolomide:		
Speci		: Rat, female	
NOAE		: 4 mg/kg	
LOAE	L ation Route	: 21 mg/kg : Oral	
	sure time	: 6 Months	
	t Organs		thymus gland, Bone marrow, Reproductive
Speci	es	: Rat, male	
NOAE		: 8.5 mg/kg	
LOAE		: 34 mg/kg	
	ation Route	: Oral	
	sure time t Organs	: 6 Months	thymus gland, Bone marrow, male reproductiv
laige	Corgano	organs, Gastro	
Speci		: Dog	
		: 2.5 mg/kg	
LOAE	ation Route	: 6.3 mg/kg : Oral	
	sure time	: 6 Months	
	t Organs		spleen, male reproductive organs, Gastrointes nus gland
<b>A</b> snir	ation toxicity		
-	assified based on av	ailable information	
	rience with human (		
-	oonents:		
Temo	zolomide:		
Ingest	tion	: Symptoms: Blo	od disorders, Nausea, Vomiting, Diarrhoea,

according to the Globally Harmonized System



# **Temozolomide Injection Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 26.09.2023
9.0		27568-00025	Date of first issue: 03.11.2014
		anorexia, Fati <u>ç</u>	gue, hair loss

### **12. ECOLOGICAL INFORMATION**

	Ecotoxicity		
	Components:		
	Citric acid:		
	Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
	Toxicity to daphnia and other aquatic invertebrates		EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h
	Sodium chloride:		
	Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l Exposure time: 96 h
	Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 4,136 mg/l Exposure time: 48 h
	Toxicity to algae/aquatic plants	:	EC50: > 2,000 mg/l Exposure time: 96 h
	Toxicity to microorganisms	:	EC10: > 1,000 mg/l
	Toxicity to fish (Chronic tox- icity)	:	NOEC: 252 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow)
	Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC: 314 mg/l Exposure time: 21 d Species: Daphnia pulex (Water flea)
I	I Temozolomide:		
	Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
	Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
	Toxicity to algae/aquatic plants	:	EC50 ( Pseudokirchneriella subcapitata (green algae)): > 90 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
			NOEC ( Pseudokirchneriella subcapitata (green algae)): 40 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

according to the Globally Harmonized System



Version 9.0	Revision Date: 28.09.2024		S Number: 568-00025	Date of last issue: 26.09.2023 Date of first issue: 03.11.2014
Toxic	city to microorganisms	:		
Pers	istence and degradabi	lity		
<u>Com</u>	ponents:			
	<b>c acid:</b> egradability	:	Biodegradation Exposure time:	
Tem	ozolomide:			
Biode	egradability	:	Result: rapidly Biodegradation Exposure time:	: 83 %
Stabi	ility in water	:	Degradation ha	lf life (DT50): < 1 d
Bioa	ccumulative potential			
<u>Com</u>	ponents:			
Citrie	c acid:			
	tion coefficient: n- nol/water	:	log Pow: -1.72	
Tem	ozolomide:			
	tion coefficient: n- nol/water	:	log Pow: 1.35	
	<b>ility in soil</b> ata available			
	e <b>r adverse effects</b> ata available			

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han-
		dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

according to the Globally Harmonized System



## Temozolomide Injection Formulation

Version	<b>Revision Date:</b>
9.0	28.09.2024

SDS Number: 27568-00025 Date of last issue: 26.09.2023 Date of first issue: 03.11.2014

#### **14. TRANSPORT INFORMATION**

#### **International Regulations**

UNRTDG

Not regulated as a dangerous good

### IATA-DGR

Not regulated as a dangerous good

### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

### 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

#### The components of this product are reported in the following inventories:

AICS		not determined
DSL	:	not determined
IECSC	:	not determined

#### **16. OTHER INFORMATION**

Revision Date	:	28.09.2024
Further information Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

according to the Globally Harmonized System



## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 26.09.2023
9.0	28.09.2024	27568-00025	Date of first issue: 03.11.2014

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN